Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, Tripathy D, Martin M, Babu G, Yardley D, Wheatley-Price P, Chan A, Vazquez RV, Nusch A, Gu E, Hu H, Pathak P, Thuerigen A, Bardia A (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S460-S460

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2021.08.516

Authors with CRIS profile

Involved external institutions

Universidad Complutense de Madrid (UCM) Spain (ES) Istituto di ricovero e cura a carattere scientifico (IRCCS) Italy (IT) Hospital de Caridade de Ijuí Brazil (BR) Harvard University United States (USA) (US) Ludwig-Maximilians-Universität (LMU) Germany (DE) University of Texas MD Anderson Cancer Center United States (USA) (US) Novartis AG Switzerland (CH) Sarah Cannon Research Institute United Kingdom United Kingdom (GB) European Institute of Oncology / Istituto Europeo di Oncologia (IEO) Italy (IT) Hospital de Sant Joan Despí Moisès Broggi Spain (ES) Ottawa Hospital Canada (CA) Breast Cancer Research Centre-Western Australia Australia (AU) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven Belgium (BE) Healthcare Global Enterprises (HCG) / ಹೆಲ್ತ್ಕೇರ್ ಗ್ಲೋಬಲ್ ಎಂಟರ್ಪ್ರೈಸಸ್ ಲಿಮಿಟೆಡ್ India (IN) Centre Hospitalier Universitaire de Liège (CHU Liège) Belgium (BE) Novartis Ireland Limited Ireland (IE)

How to cite

APA:

Fasching, P., Harbeck, N., Jerusalem, G., Colleoni, M.A., Neven, P., Franke, F.,... Bardia, A. (2021). Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials. In ANNALS OF ONCOLOGY (pp. S460-S460). AMSTERDAM: ELSEVIER.

MLA:

Fasching, Peter, et al. "Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S460-S460.

BibTeX: Download